• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在乳头状尿路上皮癌进展过程中的免疫表型和分子变化。

Immunophenotypic and molecular changes during progression of papillary urothelial carcinoma.

机构信息

Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.

Transdisciplinary Department of Medicine & Advanced Technology, Seoul National University Hospital, Seoul, Korea.

出版信息

Investig Clin Urol. 2024 Sep;65(5):501-510. doi: 10.4111/icu.20230318.

DOI:10.4111/icu.20230318
PMID:39249924
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11390262/
Abstract

PURPOSE

Urothelial carcinoma has various molecular subtypes, each with different tumor characteristics. Although it is known that molecular changes occur during tumor progression, little is known about the specifics of these changes. In this study, we performed transcriptional analysis to understand the molecular changes during tumor progression.

MATERIALS AND METHODS

Formalin-fixed, paraffin-embedded tumor tissues were obtained from 12 patients with muscle-invasive bladder cancer (MIBC). The invasive and non-invasive papillary areas were identified in papillary urothelial carcinoma specimens. Immunohistochemistry (IHC) and mRNA sequencing were performed for each tumor area.

RESULTS

Patients with CK5/6-negative and CK20-positive non-invasive papillary areas were selected and classified into the IHC switch subgroup (CK5/6-positive and CK20-negative in the invasive area) and the IHC unchanged subgroup (CK5/6-negative and CK20-positive in the invasive area) according to the IHC results of the invasive area. We identified differences in the mRNA expression between the non-invasive papillary and invasive areas of the papillary MIBC tissue samples. In both the non-invasive papillary and invasive areas, the IHC switch subgroup showed basal subtype gene expression, while the IHC unchanged subgroup demonstrated luminal subtype gene expression.

CONCLUSIONS

The non-invasive papillary area showed a gene expression pattern similar to that of the invasive area. Therefore, even if the non-invasive papillary area exhibits a luminal phenotype on IHC, it can have a basal subtype gene expression depending on the invasive area.

摘要

目的

尿路上皮癌具有多种分子亚型,每种亚型具有不同的肿瘤特征。虽然已知肿瘤进展过程中会发生分子变化,但这些变化的具体情况知之甚少。在本研究中,我们进行了转录分析,以了解肿瘤进展过程中的分子变化。

材料与方法

从 12 例肌层浸润性膀胱癌(MIBC)患者中获得福尔马林固定、石蜡包埋的肿瘤组织。在乳头状尿路上皮癌标本中确定侵袭性和非侵袭性乳头状区域。对每个肿瘤区域进行免疫组织化学(IHC)和 mRNA 测序。

结果

选择 CK5/6 阴性和 CK20 阳性的非侵袭性乳头状区域的患者,并根据侵袭性区域的 IHC 结果将其分为 IHC 切换亚组(侵袭性区域 CK5/6 阳性和 CK20 阴性)和 IHC 不变亚组(侵袭性区域 CK5/6 阴性和 CK20 阳性)。我们鉴定了乳头状 MIBC 组织样本中非侵袭性乳头状和侵袭性区域之间的 mRNA 表达差异。在非侵袭性乳头状和侵袭性区域中,IHC 切换亚组表现出基底亚型基因表达,而 IHC 不变亚组表现出管腔亚型基因表达。

结论

非侵袭性乳头状区域表现出与侵袭性区域相似的基因表达模式。因此,即使非侵袭性乳头状区域在 IHC 上表现出管腔表型,也可以根据侵袭性区域具有基底亚型基因表达。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6797/11390262/31246a93e4b3/icu-65-501-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6797/11390262/1a1f1724b817/icu-65-501-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6797/11390262/05a090c50cce/icu-65-501-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6797/11390262/02bc1794913c/icu-65-501-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6797/11390262/31246a93e4b3/icu-65-501-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6797/11390262/1a1f1724b817/icu-65-501-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6797/11390262/05a090c50cce/icu-65-501-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6797/11390262/02bc1794913c/icu-65-501-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6797/11390262/31246a93e4b3/icu-65-501-g004.jpg

相似文献

1
Immunophenotypic and molecular changes during progression of papillary urothelial carcinoma.在乳头状尿路上皮癌进展过程中的免疫表型和分子变化。
Investig Clin Urol. 2024 Sep;65(5):501-510. doi: 10.4111/icu.20230318.
2
Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.免疫组织化学染色分析细胞角蛋白(CK)5/6、CD44 和 CK20 作为非肌肉浸润性乳头状上尿路尿路上皮癌的预后生物标志物。
Histopathology. 2019 Feb;74(3):483-493. doi: 10.1111/his.13763. Epub 2018 Dec 2.
3
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.预测非肌肉浸润性(Ta/T1)膀胱癌的结局:基于腔面/基底表型的分子分级的作用。
Virchows Arch. 2019 Oct;475(4):445-455. doi: 10.1007/s00428-019-02593-x. Epub 2019 Jun 25.
4
Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.使用 Gata3 及细胞角蛋白 5/6、14 和 20 的有限免疫组织化学组合对肌层浸润性尿路上皮癌进行预后分层。
Ann Diagn Pathol. 2019 Dec;43:151397. doi: 10.1016/j.anndiagpath.2019.08.001. Epub 2019 Aug 3.
5
Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia.细胞角蛋白5/6、细胞角蛋白20和p16在反应性尿路上皮异型增生及尿路上皮肿瘤非侵袭性成分诊断中的应用。
Appl Immunohistochem Mol Morphol. 2012 May;20(3):264-71. doi: 10.1097/PAI.0b013e3182351ed3.
6
Transcriptional Analysis of Immunohistochemically Defined Subgroups of Non-Muscle-Invasive Papillary High-Grade Upper Tract Urothelial Carcinoma.免疫组织化学定义的非肌肉浸润性高级别上尿路尿路上皮乳头状癌亚组的转录分析。
Int J Mol Sci. 2019 Jan 29;20(3):570. doi: 10.3390/ijms20030570.
7
In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.在pT1期非肌层浸润性膀胱癌(NMIBC)中,高KRT20和低KRT5 mRNA表达可识别管腔亚型,并预测复发和生存情况。
Virchows Arch. 2017 Mar;470(3):267-274. doi: 10.1007/s00428-017-2064-8. Epub 2017 Jan 10.
8
Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.世界卫生组织/国际泌尿病理学会分类与细胞角蛋白20表达在预测低级别乳头状尿路上皮肿瘤行为中的比较
Mod Pathol. 2001 Apr;14(4):267-72. doi: 10.1038/modpathol.3880300.
9
Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma.分析上尿路尿路上皮癌中通过上尿路肿瘤起源、膀胱癌复发和肌层浸润性膀胱癌进展的生物学特征和转变。
Int J Mol Sci. 2022 May 5;23(9):5154. doi: 10.3390/ijms23095154.
10
Utility of GATA-3 and Cytokeratin 5/6 Immunostains in Separating Condyloma Acuminatum Arising in the Urinary Tract From Non-Invasive Papillary Urothelial Carcinoma.GATA-3 和细胞角蛋白 5/6 免疫染色在鉴别尿道尖锐湿疣与非浸润性乳头状尿路上皮癌中的作用。
Int J Surg Pathol. 2022 May;30(3):260-264. doi: 10.1177/10668969211052235. Epub 2021 Oct 19.

本文引用的文献

1
Comprehensive Gene Expression Analyses of Immunohistochemically Defined Subgroups of Muscle-Invasive Urinary Bladder Urothelial Carcinoma.免疫组织化学定义的浸润性膀胱癌尿路上皮癌亚组的综合基因表达分析。
Int J Mol Sci. 2021 Jan 10;22(2):628. doi: 10.3390/ijms22020628.
2
Cancer Statistics, 2021.癌症统计数据,2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
3
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.
欧洲泌尿外科学会肌层浸润性和转移性膀胱癌指南:2020 年指南摘要。
Eur Urol. 2021 Jan;79(1):82-104. doi: 10.1016/j.eururo.2020.03.055. Epub 2020 Apr 29.
4
Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma.从非肌肉浸润性到高级尿路上皮癌的进展过程中的分子变化。
Int J Cancer. 2020 May 1;146(9):2636-2647. doi: 10.1002/ijc.32737. Epub 2019 Nov 14.
5
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.欧洲泌尿外科学会非肌肉浸润性膀胱癌(TaT1 和原位癌)指南 - 2019 年更新版。
Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20.
6
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.预测非肌肉浸润性(Ta/T1)膀胱癌的结局:基于腔面/基底表型的分子分级的作用。
Virchows Arch. 2019 Oct;475(4):445-455. doi: 10.1007/s00428-019-02593-x. Epub 2019 Jun 25.
7
The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.癌症基因组图谱表达亚型分析在晚期尿路上皮癌中对检查点抑制的反应,并确定一组具有高生存概率的患者亚群。
Eur Urol. 2019 Jun;75(6):961-964. doi: 10.1016/j.eururo.2019.02.017. Epub 2019 Mar 7.
8
Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.免疫组织化学染色分析细胞角蛋白(CK)5/6、CD44 和 CK20 作为非肌肉浸润性乳头状上尿路尿路上皮癌的预后生物标志物。
Histopathology. 2019 Feb;74(3):483-493. doi: 10.1111/his.13763. Epub 2018 Dec 2.
9
Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018.膀胱癌的流行病学:2018 年系统回顾和当代危险因素更新。
Eur Urol. 2018 Dec;74(6):784-795. doi: 10.1016/j.eururo.2018.09.001. Epub 2018 Sep 26.
10
Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.尿路上皮膀胱癌的分子亚型:来自 2411 例肿瘤的荟萃分析队列研究结果。
Eur Urol. 2019 Mar;75(3):423-432. doi: 10.1016/j.eururo.2018.08.027. Epub 2018 Sep 10.